334 related articles for article (PubMed ID: 10619261)
1. CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies.
Chilosi M; Adami F; Lestani M; Montagna L; Cimarosto L; Semenzato G; Pizzolo G; Menestrina F
Mod Pathol; 1999 Dec; 12(12):1101-6. PubMed ID: 10619261
[TBL] [Abstract][Full Text] [Related]
2. CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms.
O'Connell FP; Pinkus JL; Pinkus GS
Am J Clin Pathol; 2004 Feb; 121(2):254-63. PubMed ID: 14983940
[TBL] [Abstract][Full Text] [Related]
3. p27(Kip1) immunostaining for the differential diagnosis of small b-cell neoplasms in trephine bone marrow biopsies.
Kremer M; Dirnhofer S; Nickl A; Hoefler H; Quintanilla-Martínez L; Fend F
Mod Pathol; 2001 Oct; 14(10):1022-9. PubMed ID: 11598173
[TBL] [Abstract][Full Text] [Related]
4. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.
Bayer-Garner IB; Sanderson RD; Dhodapkar MV; Owens RB; Wilson CS
Mod Pathol; 2001 Oct; 14(10):1052-8. PubMed ID: 11598177
[TBL] [Abstract][Full Text] [Related]
5. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis.
Martín P; Santón A; Bellas C
Histopathology; 2004 Apr; 44(4):375-80. PubMed ID: 15049904
[TBL] [Abstract][Full Text] [Related]
6. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients.
Kara IO; Sahin B; Paydas S; Cetiner S
Saudi Med J; 2004 Nov; 25(11):1587-92. PubMed ID: 15573184
[TBL] [Abstract][Full Text] [Related]
7. Utility of CD138 (syndecan-1) in distinguishing carcinomas from mesotheliomas.
Saqi A; Yun SS; Yu GH; Alexis D; Taub RN; Powell CA; Borczuk AC
Diagn Cytopathol; 2005 Aug; 33(2):65-70. PubMed ID: 16007640
[TBL] [Abstract][Full Text] [Related]
8. Extranodal marginal zone B cell lymphomas of the uvea: an analysis of 13 cases.
Coupland SE; Foss HD; Hidayat AA; Cockerham GC; Hummel M; Stein H
J Pathol; 2002 Jul; 197(3):333-40. PubMed ID: 12115879
[TBL] [Abstract][Full Text] [Related]
9. Intravascular large B-cell lymphoma: the CD5 antigen is expressed by a subset of cases.
Khalidi HS; Brynes RK; Browne P; Koo CH; Battifora H; Medeiros LJ
Mod Pathol; 1998 Oct; 11(10):983-8. PubMed ID: 9796727
[TBL] [Abstract][Full Text] [Related]
10. B-cell non-Hodgkin lymphomas in Uganda: an immunohistochemical appraisal on tissue microarray.
Tumwine LK; Campidelli C; Righi S; Neda S; Byarugaba W; Pileri SA
Hum Pathol; 2008 Jun; 39(6):817-23. PubMed ID: 18436278
[TBL] [Abstract][Full Text] [Related]
11. Syndecan-1 in B lymphoid malignancies.
Sanderson RD; Børset M
Ann Hematol; 2002 Mar; 81(3):125-35. PubMed ID: 11904737
[TBL] [Abstract][Full Text] [Related]
12. Plasmablastic lymphoma: a clinicopathologic correlation.
Folk GS; Abbondanzo SL; Childers EL; Foss RD
Ann Diagn Pathol; 2006 Feb; 10(1):8-12. PubMed ID: 16414538
[TBL] [Abstract][Full Text] [Related]
13. Contribution of flow cytometric immunophenotyping and bone marrow trephine biopsy in the detection of lymphoid bone marrow infiltration in non-Hodgkin's lymphomas.
Mazur G; Hałoń A; Wróbel T; Jeleń M; Kuliczkowski K
Neoplasma; 2004; 51(3):159-63. PubMed ID: 15254666
[TBL] [Abstract][Full Text] [Related]
14. Identification of cyclin D1 mRNA overexpression in B-cell neoplasias by real-time reverse transcription-PCR of microdissected paraffin sections.
Specht K; Kremer M; Müller U; Dirnhofer S; Rosemann M; Höfler H; Quintanilla-Martinez L; Fend F
Clin Cancer Res; 2002 Sep; 8(9):2902-11. PubMed ID: 12231535
[TBL] [Abstract][Full Text] [Related]
15. The Mi15 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens.
Costes V; Magen V; Legouffe E; Durand L; Baldet P; Rossi JF; Klein B; Brochier J
Hum Pathol; 1999 Dec; 30(12):1405-11. PubMed ID: 10667416
[TBL] [Abstract][Full Text] [Related]
16. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma.
Lin P; Owens R; Tricot G; Wilson CS
Am J Clin Pathol; 2004 Apr; 121(4):482-8. PubMed ID: 15080299
[TBL] [Abstract][Full Text] [Related]
17. [Importance of selected laboratory indicators in the differential diagnosis and monitoring of multiple myeloma].
Maisnar V; Tousková M; Malý J; Krejsek J; Kmonícek M; Kopecký O
Vnitr Lek; 2002 Apr; 48(4):290-7. PubMed ID: 12061177
[TBL] [Abstract][Full Text] [Related]
18. The sensitivity of CD138 immunostaining of bone marrow trephine specimens for quantifying marrow involvement in MGUS and myeloma, including samples with a low percentage of plasma cells.
Ng AP; Wei A; Bhurani D; Chapple P; Feleppa F; Juneja S
Haematologica; 2006 Jul; 91(7):972-5. PubMed ID: 16818287
[TBL] [Abstract][Full Text] [Related]
19. Utility of CD56 immunohistochemical studies in follow-up of plasma cell myeloma.
Harrington AM; Hari P; Kroft SH
Am J Clin Pathol; 2009 Jul; 132(1):60-6. PubMed ID: 19864234
[TBL] [Abstract][Full Text] [Related]
20. Utilization of monoclonal antibody L26 in the identification and confirmation of B-cell lymphomas. A sensitive and specific marker applicable to formalin-and B5-fixed, paraffin-embedded tissues.
Cartun RW; Coles FB; Pastuszak WT
Am J Pathol; 1987 Dec; 129(3):415-21. PubMed ID: 3322020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
